Sun Pharma Completes Phase-3 Trials Of Ilumya For Psoriatic Arthritis

Sun Pharmaceutical Industries Ltd. on Monday said it and its subsidiaries have completed two Phase-3 clinical trials—INSPIRE-1 and INSPIRE-2—evaluating the efficacy and safety of 100 mg tildrakizumab (Ilumya) for treating active psoriatic arthritis over 24 weeks.

The drug showed improved signs and symptoms at week 24 compared to placebo, the company said in an exchange filing.

Both studies met their primary endpoint, with a higher proportion of patients achieving ACR20 response—a key measure for improvement in arthritis—compared to those on placebo. The drug is yet to receive regulatory approval for this indication, and its safety and efficacy have not been reviewed by authorities, Sun Pharma added.